A University of Colorado professor who experienced a funding freeze firsthand this year expressed relief at the program's ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following ...

The Global Fund has announced that it signed an access agreement with Gilead Sciences to procure lenacapavir, a twice-a-year injection that has a 99 per cent success rate in preventing HIV ...

These are the words of Rogers Omollo, founder and CEO of Activate Action – a youth-led non-profit organisation that supports ...

Countries like Kenya are redoubling their efforts to meet ambitious global goals to eliminate pediatric HIV/AIDS. As they develop plans for continuity of care in future health crises, hearing directly ...

Kenya is set to introduce a revolutionary injectable HIV prevention drug, Lenacapavir, becoming one of nine African nations ...

Kenya has been selected as one of the 9 early adopter countries for the rollout of Lenacapavir (LEN), a long-acting ...

The third study, Twiga , is an ongoing five-year observational study tracking comorbidities in both HIV-positive and HIV-negative individuals aged 60 and above. It was initiated to better understand ...

HIV and TB in Kenya When the immune system is weakened by the AIDS virus, people become vulnerable to many other infections. In parts of the world where both TB and AIDS are widespread, the number ...

When Grace's five-year-old daughter was admitted to hospital in Kenya with a chest infection, she didn't suspect HIV. Skip to main content. Exclusive news, ...